AbbVie Inc. (ABBV) Operating Cash Flow CAGR:29.41%(TTM)
Operating cash flow CAGR uses precomputed cash-flow statement history (cash from operations, before capital expenditures).
Over longer horizons, AbbVie Inc.'s Operating Cash Flow CAGR averages -4.32% over 3 years and 2.62% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Operating cash flow CAGR measures the compound annual growth rate of the cash AbbVie Inc. generates from its core business operations, before capital expenditures, computed from rolling-twelve-month cash-flow statement history.
ABBV Operating Cash Flow CAGR Chart
AbbVie Inc. (ABBV)
ABBV Quarterly Operating Cash Flow Growth (YoY)
Operating Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
ABBV Operating Cash Flow CAGR History
| Year | Start OCF | End OCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $18.81B | $19.03B | +$224.00M | +1.19% | +1.19% |
| 2024 | $22.84B | $18.81B | $-4.03B | -17.66% | -17.66% |
| 2023 | $24.94B | $22.84B | $-2.10B | -8.44% | -8.44% |
| 2022 | $22.78B | $24.94B | +$2.17B | +9.51% | +9.51% |
| 2021 | $17.59B | $22.78B | +$5.19B | +29.50% | +29.50% |
| 2020 | $13.32B | $17.59B | +$4.26B | +32.00% | +32.00% |
| 2019 | $13.43B | $13.32B | $-103.00M | -0.77% | -0.77% |
| 2018 | $9.96B | $13.43B | +$3.47B | +34.81% | +34.81% |
| 2017 | $7.04B | $9.96B | +$2.92B | +41.46% | +41.46% |
| 2016 | $7.54B | $7.04B | $-494.00M | -6.56% | -6.56% |
| 2015 | $3.55B | $7.54B | +$3.99B | +112.31% | +112.31% |
| 2014 | $6.27B | $3.55B | $-2.72B | -43.37% | -43.37% |
| 2013 | $6.34B | $6.27B | $-78.00M | -1.23% | -1.23% |
| 2012 | $6.25B | $6.34B | +$98.04M | +1.57% | +1.57% |
| 2011 | $4.98B | $6.25B | +$1.27B | +25.54% | +25.54% |
| 2010 | $5.37B | $4.98B | $-391.34M | -7.29% | -7.29% |
Quarterly Operating Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $3.83B | -26.6% | +134.2% |
| Q4 2025 | $5.22B | -25.7% | -26.0% |
| Q3 2025 | $7.02B | +36.3% | +29.0% |
| Q2 2025 | $5.15B | +215.2% | +126.9% |
| Q1 2025 | $1.64B | -76.8% | -59.5% |
| Q4 2024 | $7.05B | +29.4% | +48.3% |
| Q3 2024 | $5.45B | +139.9% | -28.1% |
| Q2 2024 | $2.27B | -43.8% | -64.1% |
| Q1 2024 | $4.04B | -15.0% | -3.6% |
| Q4 2023 | $4.75B | -37.2% | -36.0% |
| Q3 2023 | $7.57B | +19.9% | -0.4% |
| Q2 2023 | $6.32B | +50.7% | +26.3% |
| Q1 2023 | $4.19B | -43.6% | -14.6% |
| Q4 2022 | $7.43B | -2.3% | +46.4% |
| Q3 2022 | $7.60B | +51.9% | -4.2% |
| Q2 2022 | $5.00B | +2.0% | +2.4% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael